Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this observational study publication.

Among men with localized prostate cancer, especially with low- or intermediate-risk disease, vitamin D may serve as an important biomarker of disease aggression.

The aim of this study was to assess the relationship between adverse pathology at the time of radical prostatectomy and serum 25-hydroxyvitamin D (25-OH D) levels.

Descriptive and multivariate analyses were performed to assess the relationship between 25-OH D and adverse pathology at the time of prostatectomy.

Who Took Part

The abstract describes 1,760 men taking part.

By PubMed's age tags, the people studied were middle-aged adults and older adults, men only.

This cross-sectional study was carried out from 2009 to 2014, nested within a large epidemiologic study of 1,760 healthy controls and men undergoing prostate cancer screening.

In total, 190 men underwent radical prostatectomy in the cohort.

How the Study Was Run

Adverse pathology was defined as the presence of primary Gleason 4 or any Gleason 5 disease, or extraprostatic extension.

What Was Measured

The subject headings attached to it are Biomarkers, Chi-Square Distribution, Cross-Sectional Studies, Multivariate Analysis, Neoplasm Grading, Odds Ratio and Prostatectomy.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc in 1,760 men.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.